Denise Goode

Denise Goode serves as a Non-Executive Director at Alligator Bioscience AB since May 2022, focusing on novel science for pancreatic cancer. In addition, Denise has been the Chief Executive of QED Life Sciences Limited since November 2014, providing consultancy services to global biotech clients such as EpiEndo and Atrogi. A Non-Executive Director at Abliva AB until its successful acquisition by Pharming Group, Denise also holds a Non-Executive Director position at Neurovive. Prior experience includes nearly two decades at AstraZeneca as Executive Business Development Director, where Denise was involved in various therapy areas, and membership on the Board of Directors for AstraZeneca Ireland Operations Limited. Denise's career began at PricewaterhouseCoopers as a Senior Manager in Finance and Global Taxation after earning a Bachelor of Science degree in Zoology from The University of Manchester.